金嗓子(06896.HK)2022年淨利同比增加約49.9%至2.8億元
格隆匯3月29日丨金嗓子(06896.HK)公吿，截至2022年12月31日止年度的全年業績，集團的收益同比增加約20.9%至約人民幣9.92億元。公司權益持有人應占溢利同比增加約49.9%至約人民幣2.8億元。董事會建議向公司股東派付截至2022年12月31日止年度的末期股息每股0.36港元。末期股息須經公司股東於應屆股東周年大會上批准後方可作實，及倘獲批准，預計將於2023年6月30日或前派付。
集團乃中國領先的潤喉片製造商。2023年1月，公司榮獲廣西工業龍頭企業稱號，2022年年末，榮獲廣西品牌高品質發展論壇的最受觀眾歡迎品牌稱號及榮獲柳州民營企業納税十強稱號。2022年7月進入2021年度中國醫藥工業百強系列榜單獲獎企業。
2021年10月，在中國非處方藥企業及產品品牌2021年度綜合統計評比中，金嗓子喉片(OTC)在眾多產品品牌中脱穎而出，榮獲中國非處方藥物協會"中成藥咽喉類"第一名，並在非處方藥生產企業綜合排名中位列第43位。目前，集團已發展為一家現代綜合集團，主要從事生產及銷售潤喉片、其他藥品及生物科技食品。
2022年，北京市衞生健康委組織藥學、臨牀和中醫專家，參考用藥診療實際，制定的《新冠病毒感染者用藥目錄(第一版)》中，針對咽痛、咽乾等咽部症狀特別推薦了金嗓子喉片(OTC)。本集團在2022年全年的銷售額也錄得顯著提升。
集團的旗艦產品為於1994年推出的金嗓子喉片(OTC)。其為一種主要適用於緩解急性咽炎所致的喉痛喉乾及聲音嘶啞症狀的潤喉片。金嗓子喉片(OTC)已獲國家藥品監督管理局批准為非處方藥。因此，公眾無需合資格專業醫護人員的處方即可於藥房購買。截至2022年12月31日止年度，集團的金嗓子喉片(OTC)銷售額約佔其收益總額的91.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
